Literature DB >> 3856625

The pectoralis major myocutaneous flap for intraoral reconstruction: surgical complications and their treatment.

M Ueda, S Torii, M Nagayama, T Kaneda, T Oka.   

Abstract

The pectoralis major myocutaneous (PM-MC) flap was used for intra-oral reconstruction in 7 patients. Major necrosis did not occur in any of the cases, but minor necrosis did in two cases. In 2 cases an oro-cutaneous fistula was observed. Furthermore, in 2 cases severe facial oedema was experienced, which seemed attributable to circulatory disturbance in the part of the face where the flap was inserted. Muscle atrophy of the flap was observed in greater or lesser degree in all cases. In all cases the pectoralis major myocutaneous flap was used for the purpose of intraoral reconstruction. Intraoral reconstruction involves considerations different from transplantation in other sites. It is the purpose of this paper to present an updated review of our experience with 7 consecutive pectoralis major myocutaneous flaps, including the complications and their treatment.

Entities:  

Mesh:

Year:  1985        PMID: 3856625     DOI: 10.1016/s0301-0503(85)80006-0

Source DB:  PubMed          Journal:  J Maxillofac Surg        ISSN: 0301-0503


  3 in total

1.  The indications and complications of pectoralis major myocutaneous flap reconstruction in head and neck surgery-our experience.

Authors:  S Sharma; P S Murty; P Hazarika; D R Nayak; S Sharma
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  1998-10

2.  A modification of the pectoralis major myocutaneous flap that reduces the defect at the donor site.

Authors:  R Crosher; J Llewelyn; R Mitchell
Journal:  Ann R Coll Surg Engl       Date:  1995-09       Impact factor: 1.891

3.  Prolonged facial edema is an indicator of poor prognosis in patients with head and neck squamous cell carcinoma.

Authors:  Ming-Huang Chen; Peter Mu-Hsin Chang; Po-Min Chen; Cheng-Hwai Tzeng; Pen-Yuan Chu; Shyue-Yih Chang; Muh-Hwa Yang
Journal:  Support Care Cancer       Date:  2009-10-12       Impact factor: 3.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.